LBCTR2023045220 | P-SP420-THAL-01 | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent β-thalassemia | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent β-thalassemia | Interventional | Pending | 13/12/2022 |
LBCTR2019020179 | PTG300-02 | A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects with Chronic Anemia | A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects with Chronic Anemia | Interventional | Complete | 02/01/2019 |
LBCTR2019070220 | PTG300-03 | An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects | An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects | Interventional | Complete | 03/04/2019 |
LBCTR2023015206 | R34MH121558 | Young adults as community mental health workers in humanitarian settings | Young adults as community mental health workers in humanitarian settings: A pilot test of the mechanisms of effect on their own well-being | Interventional | Pending | 24/11/2022 |
LBCTR2018090151 | Rasha123 | Rasha 123 | Rasha 123 | Observational | Complete | 15/09/2018 |
LBCTR2022095104 | RBSC2161 | Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | Interventional | Complete | 27/07/2022 |
LBCTR2019040213 | ReDA_012540 | Phone-Delivered Psychological Intervention (t-CETA) for Mental Health Problems in 8-17 Year-Old Syrian Refugee Children | Development, Piloting and Evaluation of a Phone-Delivered Psychological Intervention (t-CETA) for Syrian Refugee Children in Lebanon: Phase II | Interventional | Complete | 17/02/2020 |
LBCTR2023055223 | RLY5016-208p | Patiromer for treatment of hyperkalaemia in children from birth to <6 years of age | A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 6 Years of Age with Hyperkalaemia (EMERALD 2) | Interventional | Other | 14/12/2022 |
LBCTR2019030200 | RTH258B2302 | A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema | A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema | Interventional | Complete | 20/02/2019 |
LBCTR2021104870 | SBS-2021-0102 | The effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in Lebanon | The effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in Lebanon | Interventional | Pending | 13/10/2021 |